Objective To investigate the value of thromboelastography (TEG) in analyzing blood hypercoagulability and ischemic events after percutaneous coronary intervention (PCI) in coronary heart disease (CHD) patients with anti-platelet drug therapy.
Methods A total of 118 CHD patients with PCI were selected as objects, and they were divided into TEG group and routine group according to whether TEG was taken after operation. The result of TEG and coagulation indexes were compared between the two groups, and the incidence of ischemic events and bleeding events at 6 months after surgery was observed.
Results There were no significant differences in clinical materials between the TEG group and routine group (P>0.05). The coagulation reaction time (R), kinetics of clot development (K), inhibition rates of arachidonic acid (AA) and adenosine diphosphate (ADP) in the TEG group were significantly higher than those in the routine group, while the speed of blood clot formation (α angle) and maximum amplitude of clot (MA) were significantly lower than those in the routine group (P < 0.05). Prothrombin time (PT) and fibrinogen (FIB) in the TEG group were significantly lower than those in the routine group, while activated partial thromboplastin time (APTT) and thrombin time (TT) were significantly higher than those in routine group (P < 0.05). There were significant differences in the incidence rates of ischemic events and bleeding events at 6 months after operation between the two groups (P < 0.05).
Conclusion TEG-guided anti-platelet drug therapy is beneficial to the rapid improvement of blood hypercoagulability after PCI in CHD patients, which can reduce the incidence rates of ischemia and bleeding events after PCI in CHD patients.
DownLoad: